PROCEPT BioRobotics Corp
For the period ended Sep 30, 2025. Filed Nov 5, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 5, 2025
PRCT$23.05+3.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 1. Condensed Consolidated Financial Statements (unaudited)
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except per share data)
| September 30, | December 31, | |
|---|---|---|
| 2025 | 2024 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $294,281 | $333,725 |
| Accounts receivable, net | 84,504 | 83,496 |
| Inventory | 66,715 | 56,168 |
| Prepaid expenses and other current assets | 9,252 | 8,453 |
| Total current assets | 454,752 | 481,842 |
| Restricted cash, non-current | 3,038 | 3,038 |
| Property and equipment, net | 30,022 | 26,709 |
| Operating lease right-of-use assets, net | 17,904 | 18,941 |
| Intangible assets, net | 727 | 932 |
| Other assets | 5,098 | 2,555 |
| Total assets | $511,541 | $534,017 |
| Liabilities and Stockholders' Equity | ||
| Current liabilities: | ||
| Accounts payable | $11,118 | $10,032 |
| Accrued compensation | 21,797 | 21,537 |
| Deferred revenue | 10,665 | 9,565 |
| Operating lease, current | 2,135 | 1,910 |
| Loan facility liability | — | 2,000 |
| Other current liabilities | 8,183 | 8,089 |
| Total current liabilities | 53,898 | 53,133 |
| Long-term debt | 51,566 | 51,472 |
| Operating lease, non-current | 25,225 | 26,868 |
| Other liabilities | 576 | 324 |
| Total liabilities | 131,265 | 131,797 |
| Commitments and contingencies (see Note 12) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.00001 par value; | ||
| Issued and outstanding shares: none at September 30, 2025 and December 31, 2024 | — | — |
| Common stock, $0.00001 par value; | ||
| Issued and outstanding shares: 55,870 and 54,718 at September 30, 2025 and December 31, 2024, respectively | — | — |
| Additional paid-in capital | 991,945 | 948,091 |
| Accumulated other comprehensive gain | 42 | 114 |
| Accumulated deficit | (611,711) | (545,985) |
| Total stockholders’ equity | 380,276 | 402,220 |
| Total liabilities and stockholders’ equity | $511,541 | $534,017 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.